StockMacro
Menu

Neuropace

$7.95 -52% in 6 monthsMarket cap $273.9M

NPCE on XNAS, Health Care, Neuropace, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 39% in one month as quarterly revenue dropped 16% to $23.1M.

  • GoodThree insiders bought $302K of shares in the last 90 days
  • GoodFederal contracts and grants rose to $2.1M from $368K a year earlier

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
216
Website
neuropace.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 2 Mar 2027 (an estimate: a year ago it reported on 3 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $23.1M, net loss $3.3M.
Quarter to 31 Dec 2021: revenue $11.0M, net income -$10.7MQuarter to 31 Dec 2021: revenue $11.0M, net income -$10.7MQuarter to 31 Mar 2022: revenue $11.4M, net income -$11.5MQuarter to 31 Mar 2022: revenue $11.4M, net income -$11.5MQuarter to 30 Jun 2022: revenue $10.2M, net income -$12.7MQuarter to 30 Jun 2022: revenue $10.2M, net income -$12.7MQuarter to 30 Sep 2022: revenue $11.2M, net income -$11.8MQuarter to 30 Sep 2022: revenue $11.2M, net income -$11.8MQuarter to 31 Dec 2022: revenue $12.8M, net income -$11.1MQuarter to 31 Dec 2022: revenue $12.8M, net income -$11.1MQuarter to 31 Mar 2023: revenue $14.5M, net income -$10.4MQuarter to 31 Mar 2023: revenue $14.5M, net income -$10.4MQuarter to 30 Jun 2023: revenue $16.5M, net income -$9.1MQuarter to 30 Jun 2023: revenue $16.5M, net income -$9.1MQuarter to 30 Sep 2023: revenue $16.4M, net income -$7.3MQuarter to 30 Sep 2023: revenue $16.4M, net income -$7.3MQuarter to 31 Dec 2023: revenue $18.0M, net income -$6.2MQuarter to 31 Dec 2023: revenue $18.0M, net income -$6.2MQuarter to 31 Mar 2024: revenue $18.1M, net income -$8.9MQuarter to 31 Mar 2024: revenue $18.1M, net income -$8.9MQuarter to 30 Jun 2024: revenue $19.3M, net income -$7.5MQuarter to 30 Jun 2024: revenue $19.3M, net income -$7.5MQuarter to 30 Sep 2024: revenue $21.1M, net income -$5.5MQuarter to 30 Sep 2024: revenue $21.1M, net income -$5.5MQuarter to 31 Dec 2024: revenue $21.5M, net income -$5.2MQuarter to 31 Dec 2024: revenue $21.5M, net income -$5.2MQuarter to 31 Mar 2025: revenue $22.5M, net income -$6.6MQuarter to 31 Mar 2025: revenue $22.5M, net income -$6.6MQuarter to 30 Jun 2025: revenue $23.5M, net income -$8.7MQuarter to 30 Jun 2025: revenue $23.5M, net income -$8.7MQuarter to 30 Sep 2025: revenue $27.4M, net income -$3.5MQuarter to 30 Sep 2025: revenue $27.4M, net income -$3.5MQuarter to 31 Dec 2025: revenue $26.6M, net income -$2.7MQuarter to 31 Dec 2025: revenue $26.6M, net income -$2.7MQuarter to 31 Mar 2026: revenue $22.1M, net income -$6.7MQuarter to 31 Mar 2026: revenue $22.1M, net income -$6.7MQuarter to 30 Jun 2026: revenue $22.8M, net income -$6.2MQuarter to 30 Jun 2026: revenue $22.8M, net income -$6.2MQuarter to 30 Sep 2026: revenue $23.1M, net income -$3.3MQuarter to 30 Sep 2026: revenue $23.1M, net income -$3.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $27.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$23.1M-$3.3M
30 Jun 2026$22.8M-$6.2M
31 Mar 2026$22.1M-$6.7M
31 Dec 2025$26.6M-$2.7M
30 Sep 2025$27.4M-$3.5M
30 Jun 2025$23.5M-$8.7M
31 Mar 2025$22.5M-$6.6M
31 Dec 2024$21.5M-$5.2M
30 Sep 2024$21.1M-$5.5M
30 Jun 2024$19.3M-$7.5M
31 Mar 2024$18.1M-$8.9M
31 Dec 2023$18.0M-$6.2M
30 Sep 2023$16.4M-$7.3M
30 Jun 2023$16.5M-$9.1M
31 Mar 2023$14.5M-$10.4M
31 Dec 2022$12.8M-$11.1M
30 Sep 2022$11.2M-$11.8M
30 Jun 2022$10.2M-$12.7M
31 Mar 2022$11.4M-$11.5M
31 Dec 2021$11.0M-$10.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $94.6M $86.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +8.9% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$18.9M -$24.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.56 -$0.75
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 81.4% 79.4% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -15.4% -24.2% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -20.0% -27.6% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -126% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$12.4M -$16.6M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $49.2M $60.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $59.2M $58.7M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $9.9M -$1.3M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 5.1 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.33
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.9 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.0 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 23.8 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
NeuropaceNPCE (this company) $273.9Mloss2.9+8.9%-20.0%
Treace Medical ConceptsTMCI $282.6Mloss1.4-7.1%-27.4%
InfuSystemINFU $287.5M30.52.0+2.4%6.5%
SS Innovations InternationalSSII $254.9Mloss5.5+27%-31.5%
Orthofix MedicalOFIX $247.4Mloss0.30+2.1%-5.4%
OraSure TechnologiesOSUR $238.9Mloss2.1-7.5%-41.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$302K

bought $302K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-9.7%

102 13F filers vs 113

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

77%

26.5M shares held by 13F filers (30 Sep 2026) of 34.5M outstanding (10 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.5%

858K shares sold short (30 Oct 2026) of 34.5M outstanding (10 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.5

858K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-3.1%

886K shares sold short in the report before, 858K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

51%

51% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

21

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-16%

$23.1M vs $27.4M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$2.1M

the 12 months before: $368K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$140K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

28

28 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.0×

28 articles in the last 7 days; its usual week has 3.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Insider buying $302K, 3 insiders

Price $7.95 on 20 Nov 2026, -41% over 12 months (12-month range $7.56 to $19.29)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $97K in the last 12 months (the 12 months before: -$53.3M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.
Revenue per quarter. Revenue $23.1M in the latest quarter, -16% on a year earlier.
Capital spending per quarter. Capital spending $16K in the latest quarter, -47% on a year earlier.
Institutional holders (13F filers). 102 13F filers reported holding it in the latest 13F quarter, +31% on a year earlier.
Federal obligations. Federal obligations: $285K published in the last 12 months, -86% on the 12 months before.
Lobbying spend. Lobbying spend: $140K published in the last 12 months, +75% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
18 Nov 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 302K)
28 Oct 2025Sharp changeShort interest spike: short interest spike, 1.1M vs usual 375K (2025-10-15); 2.1x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 1.1M vs usual 375K (2025-09-30); 2.1x the same period a year earlier
2 Sep 2025Sharp changeShort interest spike: short interest spike, 997K vs usual 375K (2025-08-15); 2.0x the same period a year earlier
12 Aug 2025Sharp changeShort interest spike: short interest spike, 1.1M vs usual 375K (2025-07-31); 2.3x the same period a year earlier
24 Jun 20258-K and other filingsDirector or officer change
24 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Jun 20258-K and other filingsA major agreement ended
8 May 2025Lobbying filingnew lobbying registration (LMH STRATEGIC SOLUTIONS)
8 May 2025Sharp changeFirst lobbying registration: first lobbying registration: NEUROPACE, INC.: new lobbying registration (LMH STRATEGIC SOLUTIONS)
8 Jan 20258-K and other filingsDirector or officer change
8 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Oct 2024Sharp changeShort interest spike: short interest spike, 509K vs usual 111K (2024-10-15); 1.6x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 533K vs usual 111K (2024-09-30); 1.7x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 506K vs usual 111K (2024-09-13); 1.4x the same period a year earlier
17 Sep 2024Sharp changeShort interest spike: short interest spike, 518K vs usual 111K (2024-08-30); 1.2x the same period a year earlier
7 Feb 20248-K and other filingsDirector or officer change
7 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Nov 2023Sharp changeQuarterly revenue change: quarterly revenue change, 16.4M vs usual 11.3M (2023-09-30); 1.5x the same period a year earlier
15 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 16.5M vs usual 11.3M (2023-06-30); 1.6x the same period a year earlier
19 Jul 20238-K and other filingsDirector or officer change
28 Jun 20238-K and other filingsDirector or officer change
13 Apr 20238-K and other filingsDirector or officer change
13 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Jan 20238-K and other filingsDirector or officer change
9 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: -$11K published
Month from 1 Jun 2022: -$14K published
Month from 1 Nov 2022: $585K published
Month from 1 Oct 2023: -$75K published
Month from 1 Nov 2023: -$99K published
Month from 1 Dec 2023: -$395K published
Month from 1 Jan 2024: -$12K published
Month from 1 Feb 2024: -$474K published
Month from 1 Apr 2024: -$8.2M published
Month from 1 May 2024: -$409K published
Month from 1 Oct 2024: -$1.9M published
Month from 1 Jan 2025: -$48K published
Month from 1 Feb 2025: -$50.6M published
Month from 1 May 2025: -$2.7M published
Month from 1 Mar 2026: -$399K published
Month from 1 Nov 2026: $302K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 1 published
Revenue per quarter
Quarter ended 31 Dec 2020: $10.8M; public on 11 Mar 2022
Quarter ended 31 Dec 2021: $11.0M, +2.3% on a year earlier; public on 11 Mar 2022
Quarter ended 31 Mar 2022: $11.4M, +1.4% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $10.2M, -19% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $11.2M, +7.9% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $12.8M, +16% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $14.5M, +27% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $16.5M, +62% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $16.4M, +47% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $18.0M, +41% on a year earlier; public on 6 Mar 2024
Quarter ended 31 Mar 2024: $18.1M, +25% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $19.3M, +17% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $21.1M, +28% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $21.5M, +19% on a year earlier; public on 5 Mar 2025
Quarter ended 31 Mar 2025: $22.5M, +24% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $23.5M, +22% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $27.4M, +30% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $26.6M, +24% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $22.1M, -2.0% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $22.8M, -3.0% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $23.1M, -16% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $46K; public on 11 Mar 2022
Quarter ended 31 Dec 2021: $154K, +235% on a year earlier; public on 11 Mar 2022
Quarter ended 31 Mar 2022: $306K, +774% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $164K, +865% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $31K, -83% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $102K, -34% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $132K, -57% on a year earlier; public on 5 May 2023
Quarter ended 30 Sep 2023: $9K, -71% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $32K, -69% on a year earlier; public on 6 Mar 2024
Quarter ended 31 Mar 2024: $104K, -21% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $63K; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $100K, +1011% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $39K, +22% on a year earlier; public on 5 Mar 2025
Quarter ended 31 Mar 2025: $37K, -64% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $168K, +167% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $30K, -70% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $97K, +149% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $117K, +216% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $125K, -26% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $16K, -47% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 39; public on 14 Feb 2022
31 Mar 2022 report: 38; public on 16 May 2022
30 Jun 2022 report: 32; public on 15 Aug 2022
30 Sep 2022 report: 27; public on 14 Nov 2022
31 Dec 2022 report: 23; public on 14 Feb 2023
31 Mar 2023 report: 23; public on 15 May 2023
30 Jun 2023 report: 21; public on 14 Aug 2023
30 Sep 2023 report: 24; public on 14 Nov 2023
31 Dec 2023 report: 37; public on 14 Feb 2024
31 Mar 2024 report: 53; public on 15 May 2024
30 Jun 2024 report: 51; public on 14 Aug 2024
30 Sep 2024 report: 47; public on 14 Nov 2024
31 Dec 2024 report: 62; public on 14 Feb 2025
31 Mar 2025 report: 90; public on 15 May 2025
30 Jun 2025 report: 95; public on 14 Aug 2025
30 Sep 2025 report: 78; public on 14 Nov 2025
31 Dec 2025 report: 98; public on 17 Feb 2026
31 Mar 2026 report: 108; public on 15 May 2026
30 Jun 2026 report: 113; public on 14 Aug 2026
30 Sep 2026 report: 102; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $35K published
Month from 1 Jan 2022: $46K published
Month from 1 Feb 2022: $85K published
Month from 1 Mar 2022: $1K published
Month from 1 Apr 2022: $43K published
Month from 1 Aug 2022: $2.6M published
Month from 1 Oct 2022: $119K published
Month from 1 Jan 2023: $11K published
Month from 1 Feb 2023: $48K published
Month from 1 Apr 2023: $43K published
Month from 1 Jun 2023: $3.0M published
Month from 1 Jul 2023: $44K published
Month from 1 Jan 2024: $44K published
Month from 1 Feb 2024: $101K published
Month from 1 Apr 2024: -$40K published
Month from 1 Jul 2024: $36K published
Month from 1 Aug 2024: $1.7M published
Month from 1 Sep 2024: $46K published
Month from 1 Nov 2024: $46K published
Month from 1 Mar 2025: $94K published
Month from 1 Apr 2025: $51K published
Month from 1 May 2025: $56K published
Month from 1 Jun 2025: $27K published
Month from 1 Jul 2025: $47K published
Month from 1 Aug 2025: $16K published
Month from 1 Sep 2025: $1.7M published
Month from 1 Oct 2025: $60K published
Month from 1 Nov 2025: $66K published
Month from 1 Dec 2025: $38K published
Month from 1 Jan 2026: $115K published
Month from 1 Mar 2026: $84K published
Month from 1 Jun 2026: $48K published
Month from 1 Oct 2026: -$200 published
Lobbying spend
Quarter from 1 Jul 2025: $30K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $30K published
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Made public in the last 90 days: it had 3 insiders buy $302K of its shares on the open market within 30 days (3 filings).
  • Clustered insider buying: had 3 insiders buy $302K of its shares on the open market within 30 days (3 filings) Public on 18 Nov 2026.
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months.
  • Revenue per quarter: Revenue $23.1M in the latest quarter, -16% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 37 insider trades

Last 90 days: no sales; 3 purchases, $302K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026R Scott HuennekensDirectorBuy12,500$8.29$104KForm 4
17 Nov 2026Patrick F. WilliamsChief Financial OfficerBuy11,891$8.34$99KForm 4
17 Nov 2026Joel BeckerCHIEF EXECUTIVE OFFICERBuy11,891$8.35$99KForm 4
4 Mar 2026Martha MorrellCHIEF MEDICAL OFFICERSell25,000$15.97$399KForm 4
16 May 2025Orbimed Advisors LLC and 1 other10% ownerSell168,136$15.85$2.7MForm 4
25 Feb 2025Martha MorrellCHIEF MEDICAL OFFICERSell78,334$13.72$1.1MForm 4
20 Feb 2025KCK Ltd.10% ownerSell5,270,845$9.40$49.5MForm 4
31 Jan 2025Martha MorrellCHIEF MEDICAL OFFICERSellplanned in advance (10b5-1)300$15.00$4KForm 4

102 institutions reported shares at the end of Q3 2026, 77% of the shares outstanding; 14 opened a position, 22 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
First Light Asset Management, LLC4.0M11.6%$54.8M+1.1M+39%
Polar Capital Holdings Plc3.3M9.57%$45.4MNo change
Soleus Capital Management, L.P.3.2M9.34%$44.3M+307K+11%
Morgan Stanley2.6M7.46%$35.3M-86K-3.2%
BlackRock, Inc.2.5M7.16%$34.0M-10K-0.4%
Driehaus Capital Management LLC1.4M4.15%$19.7M-18K-1.2%
Vanguard Capital Management LLC1.2M3.58%$17.0M+7,103+0.6%
Orbimed Advisors LLC1.1M3.06%$14.5M-450K-30%
Deutsche Bank AG\936K2.72%$12.9M-3,267-0.3%
Armistice Capital, LLC800K2.32%$11.0M+108K+16%

Company events

All 17 company events

Nothing in 12 months; the latest was filed 24 Jun 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
24 Jun 2025Director or officer change8-K
4 Jun 2025Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
14 Feb 2025Signed a major agreement8-K
8 Jan 2025Director or officer change8-K
7 Feb 2024Director or officer change8-K
4 Dec 2023Signed a major agreement8-K
19 Jul 2023Director or officer change8-K
28 Jun 2023Director or officer change8-K

21 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 90%, Finance & accounting 5%, Test, quality & reliability 5%.

PostedJobLocation
20 Nov 2026Associate Therapy Consultant - FresnoSales & business developmentFresno, California
20 Nov 2026Associate Therapy Consultant - BirminghamSales & business developmentBirmingham, AL
19 Nov 2026Associate Therapy Consultant - San Francisco Bay AreaSales & business developmentSan Francisco, CA
18 Nov 2026Associate Therapy Consultant - Fort WorthSales & business developmentFort Worth, Texas
17 Nov 2026Associate Therapy Consultant - CharlestonSales & business developmentCharleston, South Carolina
12 Nov 2026Therapy Consultant - DetroitSales & business developmentDetroit, Michigan
12 Nov 2026Associate Therapy Consultant - IndianapolisSales & business developmentIndianapolis, IN
12 Nov 2026Associate Therapy Consultant - Grand RapidsSales & business developmentGrand Rapids, Michigan

Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 May 2025NewLMH Strategic Solutionsfor Neuropace, Inc.Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.Medicare/MedicaidFiling

The 5 newest of 159 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 18 Nov 2026Insiders change

    had 3 insiders buy $302K of its shares on the open market within 30 days (3 filings).

    Who bought: Becker Joel, Williams Patrick F., Huennekens R Scott.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $302K
    Window
    19 Oct 2026 to 18 Nov 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  2. 18 Nov 2026Insiders record

    Huennekens R Scott (director) bought 12,500 shares of NPCE ($103,661)

  3. 17 Nov 2026Insiders record

    Williams Patrick F. (Chief Financial Officer) bought 11,891 shares of NPCE ($99,148)

  4. 17 Nov 2026Insiders record

    Becker Joel (CHIEF EXECUTIVE OFFICER) bought 11,891 shares of NPCE ($99,293)

  5. 25 Oct 2025Short interest and volume change

    had 1.1M shares sold short in the 15 Oct 2025 report, 2.1× the same report last year.

    Same report last year: 509K; its normal report is 375K.

    See the evidence
    This period
    1.1M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    125K
    How far from its usual level
    +3.8
    Same report last year
    509K
    History used
    1,629 days
    2024-10-15: 509K2024-10-31: 438K2024-11-15: 290K2024-11-29: 249K2024-12-13: 251K2024-12-31: 263K2025-01-15: 267K2025-01-31: 219K2025-02-14: 228K2025-02-28: 246K2025-03-14: 308K2025-03-31: 450K2025-04-15: 347K2025-04-30: 394K2025-05-15: 400K2025-05-30: 356K2025-06-13: 357K2025-06-30: 782K2025-07-15: 897K2025-07-31: 1.1M2025-08-15: 997K2025-08-29: 1.0M2025-09-15: 945K2025-09-30: 1.1M2025-10-15: 1.1M
    the 15 Oct 2025 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 10 Oct 2025Short interest and volume change

    had 1.1M shares sold short in the 30 Sep 2025 report, 2.1× the same report last year.

    Same report last year: 533K; its normal report is 375K.

    See the evidence
    This period
    1.1M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    125K
    How far from its usual level
    +4.0
    Same report last year
    533K
    History used
    1,614 days
    2024-09-30: 533K2024-10-15: 509K2024-10-31: 438K2024-11-15: 290K2024-11-29: 249K2024-12-13: 251K2024-12-31: 263K2025-01-15: 267K2025-01-31: 219K2025-02-14: 228K2025-02-28: 246K2025-03-14: 308K2025-03-31: 450K2025-04-15: 347K2025-04-30: 394K2025-05-15: 400K2025-05-30: 356K2025-06-13: 357K2025-06-30: 782K2025-07-15: 897K2025-07-31: 1.1M2025-08-15: 997K2025-08-29: 1.0M2025-09-15: 945K2025-09-30: 1.1M
    the 30 Sep 2025 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 27 Aug 2025Short interest and volume change

    had 997K shares sold short in the 15 Aug 2025 report, 2.0× the same report last year.

    Same report last year: 488K; its normal report is 375K.

    See the evidence
    This period
    997K (the 15 Aug 2025 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +3.5
    Same report last year
    488K
    History used
    1,568 days
    2024-08-15: 488K2024-08-30: 518K2024-09-13: 506K2024-09-30: 533K2024-10-15: 509K2024-10-31: 438K2024-11-15: 290K2024-11-29: 249K2024-12-13: 251K2024-12-31: 263K2025-01-15: 267K2025-01-31: 219K2025-02-14: 228K2025-02-28: 246K2025-03-14: 308K2025-03-31: 450K2025-04-15: 347K2025-04-30: 394K2025-05-15: 400K2025-05-30: 356K2025-06-13: 357K2025-06-30: 782K2025-07-15: 897K2025-07-31: 1.1M2025-08-15: 997K
    the 15 Aug 2025 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 12 Aug 2025Short interest and volume change

    had 1.1M shares sold short in the 31 Jul 2025 report, 2.3× the same report last year.

    Same report last year: 478K; its normal report is 375K.

    See the evidence
    This period
    1.1M (the 31 Jul 2025 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    112K
    How far from its usual level
    +4.4
    Same report last year
    478K
    History used
    1,553 days
    2024-07-31: 478K2024-08-15: 488K2024-08-30: 518K2024-09-13: 506K2024-09-30: 533K2024-10-15: 509K2024-10-31: 438K2024-11-15: 290K2024-11-29: 249K2024-12-13: 251K2024-12-31: 263K2025-01-15: 267K2025-01-31: 219K2025-02-14: 228K2025-02-28: 246K2025-03-14: 308K2025-03-31: 450K2025-04-15: 347K2025-04-30: 394K2025-05-15: 400K2025-05-30: 356K2025-06-13: 357K2025-06-30: 782K2025-07-15: 897K2025-07-31: 1.1M
    the 31 Jul 2025 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 24 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 24 Jun 2025Filings record

    Director or officer change

  11. 4 Jun 2025Filings record

    A major agreement ended

  12. 8 May 2025Lobbying change

    registered for federal lobbying for the first time in our data (Lmh Strategic Solutions).

    See the evidence (1 source record)
    Source coverage starts
    17 Jul 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  13. 8 May 2025Lobbying record

    NEUROPACE, INC.: new lobbying registration (LMH STRATEGIC SOLUTIONS) (dated 1 May 2025)

  14. 8 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 8 Jan 2025Filings record

    Director or officer change

  16. 25 Oct 2024Short interest and volume change

    had 509K shares sold short in the 15 Oct 2024 report, 1.6× the same report last year.

    Same report last year: 313K; its normal report is 111K.

    See the evidence
    This period
    509K (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    111K
    Typical spread (median absolute deviation)
    48K
    How far from its usual level
    +5.5
    Same report last year
    313K
    History used
    1,264 days
    2023-10-13: 313K2023-10-31: 396K2023-11-15: 151K2023-11-30: 129K2023-12-15: 94K2023-12-29: 63K2024-01-12: 36K2024-01-31: 63K2024-02-15: 63K2024-02-29: 50K2024-03-15: 31K2024-03-28: 86K2024-04-15: 97K2024-04-30: 90K2024-05-15: 125K2024-05-31: 74K2024-06-14: 87K2024-06-28: 136K2024-07-15: 440K2024-07-31: 478K2024-08-15: 488K2024-08-30: 518K2024-09-13: 506K2024-09-30: 533K2024-10-15: 509K
    the 15 Oct 2024 report24 earlier reportsnormal: 111K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 10 Oct 2024Short interest and volume change

    had 533K shares sold short in the 30 Sep 2024 report, 1.7× the same report last year.

    Same report last year: 307K; its normal report is 111K.

    See the evidence
    This period
    533K (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    111K
    Typical spread (median absolute deviation)
    48K
    How far from its usual level
    +5.9
    Same report last year
    307K
    History used
    1,249 days
    2023-09-29: 307K2023-10-13: 313K2023-10-31: 396K2023-11-15: 151K2023-11-30: 129K2023-12-15: 94K2023-12-29: 63K2024-01-12: 36K2024-01-31: 63K2024-02-15: 63K2024-02-29: 50K2024-03-15: 31K2024-03-28: 86K2024-04-15: 97K2024-04-30: 90K2024-05-15: 125K2024-05-31: 74K2024-06-14: 87K2024-06-28: 136K2024-07-15: 440K2024-07-31: 478K2024-08-15: 488K2024-08-30: 518K2024-09-13: 506K2024-09-30: 533K
    the 30 Sep 2024 report24 earlier reportsnormal: 111K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 25 Sep 2024Short interest and volume change

    had 506K shares sold short in the 13 Sep 2024 report, 1.4× the same report last year.

    Same report last year: 352K; its normal report is 111K.

    See the evidence
    This period
    506K (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    111K
    Typical spread (median absolute deviation)
    48K
    How far from its usual level
    +5.5
    Same report last year
    352K
    History used
    1,232 days
    2023-09-15: 352K2023-09-29: 307K2023-10-13: 313K2023-10-31: 396K2023-11-15: 151K2023-11-30: 129K2023-12-15: 94K2023-12-29: 63K2024-01-12: 36K2024-01-31: 63K2024-02-15: 63K2024-02-29: 50K2024-03-15: 31K2024-03-28: 86K2024-04-15: 97K2024-04-30: 90K2024-05-15: 125K2024-05-31: 74K2024-06-14: 87K2024-06-28: 136K2024-07-15: 440K2024-07-31: 478K2024-08-15: 488K2024-08-30: 518K2024-09-13: 506K
    the 13 Sep 2024 report24 earlier reportsnormal: 111K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 12 Sep 2024Short interest and volume change

    had 518K shares sold short in the 30 Aug 2024 report, 1.2× the same report last year.

    Same report last year: 441K; its normal report is 111K.

    See the evidence
    This period
    518K (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    111K
    Typical spread (median absolute deviation)
    48K
    How far from its usual level
    +5.7
    Same report last year
    441K
    History used
    1,218 days
    2023-08-31: 441K2023-09-15: 352K2023-09-29: 307K2023-10-13: 313K2023-10-31: 396K2023-11-15: 151K2023-11-30: 129K2023-12-15: 94K2023-12-29: 63K2024-01-12: 36K2024-01-31: 63K2024-02-15: 63K2024-02-29: 50K2024-03-15: 31K2024-03-28: 86K2024-04-15: 97K2024-04-30: 90K2024-05-15: 125K2024-05-31: 74K2024-06-14: 87K2024-06-28: 136K2024-07-15: 440K2024-07-31: 478K2024-08-15: 488K2024-08-30: 518K
    the 30 Aug 2024 report24 earlier reportsnormal: 111K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 7 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 7 Feb 2024Filings record

    Director or officer change

  22. 7 Nov 2023Financials change

    reported revenue of $16.4M for the quarter ended 30 Sep 2023, 1.5× the same quarter last year.

    Same quarter last year: $11.2M; its normal quarter is $11.3M.

    See the evidence
    This period
    $16.4M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $11.3M
    Typical spread (median absolute deviation)
    $996K
    How far from its usual level
    +3.5
    Same quarter last year
    $11.2M
    History used
    1,278 days
    2021-09-30: $10.3M2021-12-31: $11.0M2022-03-31: $11.4M2022-06-30: $10.2M2022-09-30: $11.2M2022-12-31: $12.8M2023-03-31: $14.5M2023-06-30: $16.5M2023-09-30: $16.4M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $11.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 15 Aug 2023Financials change

    reported revenue of $16.5M for the quarter ended 30 Jun 2023, 1.6× the same quarter last year.

    Same quarter last year: $10.2M; its normal quarter is $11.3M.

    See the evidence
    This period
    $16.5M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $11.3M
    Typical spread (median absolute deviation)
    $996K
    How far from its usual level
    +3.6
    Same quarter last year
    $10.2M
    History used
    1,186 days
    2021-06-30: $12.6M2021-09-30: $10.3M2021-12-31: $11.0M2022-03-31: $11.4M2022-06-30: $10.2M2022-09-30: $11.2M2022-12-31: $12.8M2023-03-31: $14.5M2023-06-30: $16.5M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $11.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 19 Jul 2023Filings record

    Director or officer change

  25. 28 Jun 2023Filings record

    Director or officer change

  26. 13 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 13 Apr 2023Filings record

    Director or officer change

  28. 9 Jan 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 9 Jan 2023Filings record

    Director or officer change

  30. 24 Nov 2022Insiders record

    Accelmed Partners II L.P. (ten percent owner) bought 390,291 shares of NPCE ($585,436) (dated 23 Nov 2022)

  31. 19 Oct 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 19 Oct 2021Filings record

    Director or officer change

  33. 24 Apr 2021Insiders change

    had 6 insiders buy $25.1M of its shares on the open market within 30 days (6 filings).

    Who bought: Accelmed Partners II L.P., Fischer Frank M, Garfield Greg Shaw, Ridley Irina and 1 more.

    See the evidence (6 source records)
    Independent buyers
    6
    Purchase filings (Form 4, code P)
    6
    Total bought
    $25.1M
    Window
    25 Mar 2021 to 24 Apr 2021

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  34. 24 Apr 2021Insiders record

    OrbiMed Capital GP VI LLC (ten percent owner) and 1 other(s) bought 235,000 shares of NPCE ($4.0M) (dated 23 Apr 2021)

  35. 24 Apr 2021Insiders record

    Norton Evan (director) bought 588,235 shares of NPCE ($10.0M) (dated 23 Apr 2021)

  36. 24 Apr 2021Insiders record

    Ridley Irina (General Counsel and Secretary) bought 2,352 shares of NPCE ($39,984) (dated 23 Apr 2021)

  37. 24 Apr 2021Insiders record

    Garfield Greg Shaw (director) bought 13,235 shares of NPCE ($224,995) (dated 23 Apr 2021)

  38. 24 Apr 2021Insiders record

    Fischer Frank M (director) bought 50,000 shares of NPCE ($850,000) (dated 23 Apr 2021)

  39. 24 Apr 2021Insiders record

    Accelmed Partners II L.P. (ten percent owner) bought 588,235 shares of NPCE ($10.0M) (dated 23 Apr 2021)

  40. 14 Apr 2021Filings record

    Registered new securities for sale (S-1)

Showing the newest 40 of 43 entries; narrow the window or the kind of data to see older ones.

Not listed: 89 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001528287
Ticker
NPCE
Domain
neuropace.com
Employer name
NeuroPace, Inc. (1 unverified)
Hq location
CA|MOUNTAIN VIEW|94043 (1 unverified)
Lobbying client
neuropace
Name
Neuropace, Inc.
Uei
VV9XSUEG8QD3
Wikidata
Q63969967
  • DOL H-1B labor condition applications and PERM certifications15 data points9 Mar 2020 to 11 Apr 2022
  • Federal lobbying disclosures (LDA)1 record, 18 data points1 May 2025 to 30 Sep 2026
  • SEC Form 13F institutional holdings198 data points30 Jun 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)75 records9 Jan 2017 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)543 data points31 Dec 2019 to 10 Nov 2026
  • SEC Form 4 insider transactions37 records, 124 data points23 Apr 2021 to 18 Nov 2026
  • FINRA short interest (twice monthly)395 data points30 Apr 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2802 data points22 Apr 2021 to 20 Nov 2026
  • USASpending.gov federal awards231 data points27 Mar 2014 to 5 Oct 2026